Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both reports explicitly requested empirical validations of these now widely used consensus-based definitions.”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. (2006)
In the citing paper
“Not only were the specific operationalisations of the duration criteria by Frank et al. (1991) and Rush et al. (2006) not empirically supported”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. 2006
In the citing paper
“This definition of relapse is the one most commonly used in clinical studies.39”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
(1992) · PubMed · Cited by 33,716
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“These reports have relied on a variety of reasonably chosen remission end points at study exit (eg, 17-item Hamilton Rating Scale for Depression p7 or p6 (HRSD17; Hamilton, 1960, 1967) or MontgomeryÄsberg Depression Rating Scale p10 (MADRS; Montgomery and Äsberg, 1979)).”
MethodThe MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Research works printed but not linked: 2
- American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4): 1–45.
- Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B–1390B.
Cited by
Items 401–500 of 697
Sackeïm, H. A., Rush, A. J., Greco, T., Jiang, M., Badejo, S., Bunker, M. T., Aaronson, S. T., Conway, C. R., Demyttenaere, K., Young, A. H., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291722003798 · Cited by 12
“Still other patients remit with acute anti-depressant treatments, but sustained benefit is not achieved due to rapid and/or frequent relapse (Aaronson et al., 2021; Rush et al., 2006c; Sackeim et al., 2007; Singh, Fedgchin, Daly, & Drevets, 2020).”
BackgroundMethodInfluentialSelf-citationClinical correlates of complicated grief among individuals with acute coronary syndromes
Pini, S., Gesi, C., Abelli, M., Cardini, A., Lari, L., Felice, F., Stefano, R. D., Mazzotta, G., Bovenzi, F., Bertoli, D., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s87118 · Cited by 13
Helmreich, I., Wagner, S., König, J., Kohnen, R., Szegedi, A., Hiemke, C., & Tadić, A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.043 · Cited by 18
“subscales and the full HAMD17 scale according to the most commonly used criteria (Riedel et al., 2010; Rush et al., 2006): (1) EI”
MethodOne-year severity of depressive symptoms: Results from the NESDA study
Lamers, F., Beekman, A. T. F., de Jonge, P., Smit, J. H., Nolen, W. A., & Penninx, B. W. J. H. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.07.005 · Cited by 16
“Thus, we do not know for how long theMDD in the remitted group had been absent, leaving unclear how many of these persons were indeed in remission according to the frequently used definition of no significant signs or symptoms for at least 2–4 consecutive weeks (Keller, 2003; Rush et al., 2006).”
Early Complete Remitters After Electroconvulsive Therapy: Profile and Prognosis
Spaans, H., Verwijk, E., Stek, M. L., Kho, K. H., Bouckaert, F., Kok, R., & Sienaert, P. A. (2016) · Journal of Ect · doi:10.1097/yct.0000000000000298 · Cited by 15
Using daily monitoring of psychiatric symptoms to evaluate hospital length of stay
Page, A. C., Cunningham, N. K., & Hooke, G. R. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.003814 · Cited by 14
Therapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 15
Jang, Y. J., Kim, M.-J., Moon, Y. K., Lim, S., & Kim, D. K. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06683-w · Cited by 19
“The response was defined as a 50% or greater reduction in the HAM-D score at 6 weeks, while remission was defined as a HAM-D score of 7 or lower at 6 weeks of treatment [31].”
How should residual symptoms be defined in depressed patients who have remitted?
Zimmerman, M. A., Martinez, J. H., Attiullah, N., Friedman, M., Toba, C., & Boerescu, D. A. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.06.010 · Cited by 11
“to define remission [20].”
BackgroundStudying treatment-effect heterogeneity in precision medicine through induced subgroups
Sies, A., Demyttenaere, K., & Mechelen, I. V. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1579220 · Cited by 15
“Of course, although statistically less efficient, remission rates may still be clinically relevant, and the same holds for response rates (Rush et al. 2006, 2011).”
BackgroundAdjei, K., Adunlin, G., & Ali, A. A. (2023) · Healthcare · doi:10.3390/healthcare11050740 · Cited by 19
Sarfan, L. D., Zieve, G. G., Gumport, N. B., Xiong, M., & Harvey, A. G. (2023) · Behaviour Research and Therapy · doi:10.1016/j.brat.2023.104325 · Cited by 11
Spellmann, I., Schennach, R., Seemüller, F., Meyer, S., Musil, R., Jäger, M., Schmauß, M., Laux, G., Pfeiffer, H., Naber, D., et al. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0741-2 · Cited by 13
Jha, M., South, C., Trivedi, J., Minhajuddin, A., Rush, A., & Trivedi, M. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz011 · Cited by 12
Self-citationThe relationship between insomnia and major depressive disorder: a chicken and egg situation?
Güleç, M., Özcan, H., Oral, E., Selvı, Y., & Aydın, A. (2012) · Journal of Mood Disorders · doi:10.5455/jmood.20120208025502 · Cited by 12
“Similarly, the recommendation of the ACNP Task Force is to use a score of ≤7 or ≤5 on the HAMD-17 scale as criteria for full remission (6).”
BackgroundMethodInfluentialConway, C. R., Rush, A. J., Aaronson, S. T., Bunker, M. T., Gordon, C., George, M. S., Riva‐Posse, P., Allen, R. M., Nahas, Z. H., Kriedt, C. L., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf080 · Cited by 13
“When the extent of clinical benefit at 12 months was increased to SB, reflecting traditional definitions of clinical response and relapse, 28,29 rates of loss of benefit (relapse) were consistently lower at both follow-up time points, with medians of 6.7% and 7.8% at 18 and 24 months, respectively.”
InfluentialSelf-citationBuckman, J. E. J., Saunders, R., Cohen, Z. D., Clarke, K., Ambler, G., DeRubeis, R. J., Gilbody, S. M., Hollon, S. D., Kendrick, T., Watkins, E. R., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15225.3 · Cited by 12
“For those that do get treatment the majority will either not reach remission or it will take a number of trials of different treatments before they do (Kessler, 2018; Rush et al., 2006).”
SSRI withdrawal syndrome in children and adolescents: a narrative literature review
Khan, Y. S., Khoodoruth, M. A. S., Albobali, Y., & Haddad, P. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2224557 · Cited by 12
“Whilst SSRI withdrawal symptoms typically arise suddenly, and within days of stopping or reducing the dose, symptoms of a depressive relapse will have a more gradual onset, often weeks or months after stopping an antidepressant [50].”
BackgroundEffects of Anxious Depression on Antidepressant Treatment Response
Hampf, C., Scherf‐Clavel, M., Weiß, C., Klüpfel, C., Stonawski, S., Hommers, L. G., Lichter, K., Erhardt, A., Unterecker, S., Domschke, K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417128 · Cited by 14
“Severity of depressive symptoms and their change during psychopharmacotherapy were assessed weekly, using the Hamilton Depression Rating Scale (HDRS)-21 [37,38].”
MethodCohen, Z. D., Breunese, J., Markowitz, J. C., Weitz, E. S., Hollon, S. D., Browne, D. T., Rucci, P., Corda, C., Menchetti, M., Weissman, M. M., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291724001788 · Cited by 13
“Fifth, although many similarities were observed across study protocols, methodological differences did emerge in key areas, such as treatment length.”
Lin, C., Huang, C., & Chen, C. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx114 · Cited by 11
“Second, the 6-week treatment with fluoxetine might also be criticized as being of too short a duration for the stability of the result to be verified, as longer treatment durations may lead to further improvement in depressive symptoms and functioning (Kocsis et al., 2002; Rush et al., 2006).”
BackgroundAaronson, S. T., Sackeïm, H. A., Jiang, M., Badejo, S., Greco, T., Bunker, M. T., Conway, C. R., Demyttenaere, K., Young, A. H., McAllister-Williams, H., et al. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231209837 · Cited by 10
“In addition, symptomatic remission is widely considered the goal of antidepressant treat-ment (Gelenberg, 2010; Möller, 2008; Rush et al., 2006b) and commonly is the primary efficacy outcome measure.”
BackgroundMethodInfluentialSelf-citationLenox‐Smith, A., Martinez, J. M., David, P., Dowsett, S. A., Dennehy, E. B., López‐Romero, P., & Demyttenaere, K. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.08.003 · Cited by 14
“The main goal of treatment of a depressive episode is remission, often defined in clinical trials as a Hamilton Rating Scale of Depression (HAM-D17) score of 7 or less or, in clinical practice, a return to a normal or near-normal mood (Frank et al., 1991; Kupfer, 1991; Keller, 2003; Rush et al., 2006).”
BackgroundSacchetti, E., Frank, E., Siracusano, A., Racagni, G., Vita, A., & Turrina, C. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000074 · Cited by 11
“Therefore, the results of VIVAL-D-Rem support recommendations (Zimmerman et al., 2004a, 2005, 2012a; Rush et al., 2006; Möller, 2008) to lower the threshold of symptom severity to values compatible with a clinical condition of true remission.”
BackgroundResultInfluentialSelf-citationWang, G., You, X., Wang, X., Xu, X., Bai, L., Xie, J. M., Yao, Z., Yi, Q., Ma, J., Wang, J., et al. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164673 · Cited by 12
Scherf‐Clavel, M., Wurst, C., Nitschke, F., Stonawski, S., Burschka, C., Friess, L., Unterecker, S., Hommers, L. G., Deckert, J., Domschke, K., et al. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104590 · Cited by 15
Prieto-Vila, M., Estupiñá, F. J., & Vindel, A. C. (2021) · Psicothema · doi:10.7334/psicothema2020.186 · Cited by 20
“…so far has been on the effi cacy and maintenance of psychological therapies in comparison to the treatment as usual (TAU), without specifying relapse rates or studying variables that might predict recurrence (Cuijpers et al., 2009; Linde et al., 2015; Twomey et al., 2015; Santoft et al., 2019).”
ResultKurczewska, E., Ferensztajn‐Rochowiak, E., Rybakowski, F., Michalak, M., & RYBAKOWSKI, J. K. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1755449 · Cited by 14
“According to the guidelines of clinical practice (Rush et al. 2006; MacQueen et al. 2017), a reduction of 50% of points in the HDRS was considered as a criterion of clinical improvement (response), and the remission criterion was to achieve 7 points in this scale, lasting until the last (14th) day…”
MethodVittengl, J. R., & Jarrett, R. B. (2013) · Wiley eBooks · doi:10.1002/9781118528563.wbcbt48 · Cited by 13
Molero, P., Ibáñez, Á., de Diego-Adeliño, J., Ramos‐Quiroga, J. A., Dorado, M. G., Rengel, P. M. L., & Sáiz, P. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03149-z · Cited by 15
“Despite the availability of numerous effi‑ cacious antidepressants [3], a substantial pro‑ portion of patients with MDD do not achieve symptomatic remission, which, owing to its implications for function and prognosis, is con‑ sidered the goal for acute treatment of the dis‑ ease [4].”
Approach to Diagnosis and Management of Treatment-Resistant Depression
Rikhani, K., Vas, C., & Jha, M. K. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.011 · Cited by 11
Lam, R. W. M., & Annemans, L. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.6.559 · Cited by 10
Citrome, L., Gommoll, C., Tang, X., Núñez, R., & Mathews, M. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000056 · Cited by 11
“Several different measures were used in this posthoc analysis, guided by the concept of no or minimal disease-related symptoms typically used to define remission in MDD clinical trials (Rush et al., 2006; Sobocki et al., 2006).”
BackgroundMethodVeldman, E. R., Mamula, D., Jiang, H., Tiger, M., Ekman, C. J., Lundberg, J., & Svenningsson, P. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.055 · Cited by 10
Older people with depression – a three-year follow-up
Borza, T., Engedal, K., Bergh, S., & Selbæk, G. (2019) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.18.0968 · Cited by 22
Ingram, R. E. (2012) · Oxford University Press eBooks · doi:10.1093/obo/9780195389678-0171 · Cited by 9
Young, A. H., Llorca, P.-M., Fagiolini, A., Falkai, P., Cardoner, N., Nielsen, R. E., Blomqvist, O., Godinov, Y., Rive, B., Diels, J., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.124 · Cited by 9
Buckman, J. E. J., Saunders, R., Cohen, Z. D., Clarke, K., Ambler, G., DeRubeis, R. J., Gilbody, S. M., Hollon, S. D., Kendrick, T., Watkins, E. R., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15225.1 · Cited by 10
Ecological Momentary Assessment versus Weekly Questionnaire Assessment of Change in Depression
Tamm, J., Takano, K., Just, L., Ehring, T. W., Rosenkranz, T., & Kopf‐Beck, J. (2024) · Depression and Anxiety · doi:10.1155/2024/9191823 · Cited by 16
“We de fi ned intervention response as a 50 % decrease in BDI-II score from pre-to post-intervention, which is a common de fi - nition used in depression literature [42].”
Ezawa, I. D., Robinson, N., & Hollon, S. D. (2024) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-080822-040442 · Cited by 11
Dai, J., Huang, Y., Liu, J., Sun, Y., Fan, X., Tu, Y., Huang, Y., Lin, Y., Zhang, M., Bai, J., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.01.037 · Cited by 13
25(OH)D levels are decreased in patients with difficult-to-treat depression
Grudet, C., Lindqvist, D., Malm, J., Westrin, Å., & Ventorp, F. (2022) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2022.100126 · Cited by 10
“, ascribed after 3 consecutive weeks during which minimal symptom status is maintained (absence of both sadness and reduced interest/pleasure, along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) [14].”
BackgroundChappell, K., Tayeb, A. E. K. A., Colle, R., Bouligand, J., El‐Asmar, K., Gressier, F., Trabado, S., David, D. J. P., Fève, B., Becquemont, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.974570 · Cited by 9
“Responders to treatment were classified by an improved HDRS score of ≥50% relative to baseline, remitters by a HDRS score ≤7 after at least 4 weeks of treatment, as recommended by the American College of Neuropsychopharmacology (ACNP) Task Force (Rush et al., 2006).”
MethodPetrozzi, B. P., Sardinha, H., Gilles, M., & Deuschle, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-32531-6 · Cited by 9
Larsen, S. E., Sippel, L. M., & Schnurr, P. P. (2020) · Clinical Psychology Science and Practice · doi:10.1111/cpsp.12364 · Cited by 9
Park, J.-H., Lim, S., Myung, W., Park, I. H., Jang, H.-J., Kim, S., Lee, M.-S., Chang, H. S., Yum, D., Suh, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83887-6 · Cited by 9
“2 for INDELs, and (5) excluding variants detected in less than two samples.”
BackgroundKjelby, E., Gjestad, R., Fathian, F., Sinkeviciute, I., Alisauskiene, R., Anda, L. G., Løberg, E., Reitan, S. K., Joa, I., Larsen, T. K., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001679 · Cited by 11
Kishon, R., Geronazzo‐Alman, L., Westphal, M., Chen, Y., Green, D., Sarda, A., Love, M., Cheng, B., Stewart, J. W., & Hollon, S. D. (2019) · International Journal of Cognitive Therapy · doi:10.1007/s41811-019-00062-6 · Cited by 10
Zisook, S., Johnson, G. R., Hicks, P. B., Chen, P., Beresford, T. P., Michalets, J. P., Rao, S. D., Thase, M. E., WILCOX, J. A., Sevilimedu, V., et al. (2020) · Depression and Anxiety · doi:10.1002/da.23114 · Cited by 12
Self-citationRepetitive transcranial magnetic stimulation: Course and early prediction of response in depression
Gill, J., Felice, N. D., Gill, J., Page, A. C., & Hooke, G. R. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.11.018 · Cited by 9
Sackeïm, H. A., Conway, C. R., Aaronson, S. T., Bunker, M. T., Gordon, C., Lee, Y.-C. (., Shy, O., Majewski, S., Tran, Q., & Rush, A. J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.124 · Cited by 8
Self-citationDeveloping Clinically Interpretable Neuroimaging Biotypes in Psychiatry
Ahn, J., Foland‐Ross, L. C., Akiki, T. J., Boyar, L., Wydler, I., Bostian, C. M., Zhang, X., Yang, H., Ellsay, A., Ma, E. W., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.08.019 · Cited by 11
“For example, full remission may be the priority in first-episode depression, whereas partial response can be an appropriate goal in treatment-resistant cases (109).”
O’Callaghan, E., Sullivan, S., Gupta, C., Belanger, H. G., & Winsberg, M. E. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04113-9 · Cited by 9
Ito, A., Hiyoshi, F., Kanie, A., Maruyama, A., Oba, M. S., & Kito, S. (2023) · JMIR Research Protocols · doi:10.2196/49698 · Cited by 9
“However, some patients with depression do not respond to those medications, and depressive symptoms may persist for a long period without adequate improvement [3], resulting in a significant emotional and financial burden on the patients and their families [4-6].”
Petrozzi, B. P., Spangemacher, M., Deicher, A., Drews, L., Defert, J., Silva-Colmenero, A. Y., Wein, P., Riedinger, E., Gründer, G., Gilles, M., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1415505 · Cited by 12
Frequency and clinical correlates of bipolar features in acute coronary syndrome patients
Pini, S., Abelli, M., Gesi, C., Lari, L., Cardini, A., Paolo, L. D., Felice, F., Stefano, R. D., Mazzotta, G., Oligeri, C., et al. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2013.06.007 · Cited by 8
“Scores below or of 5 define the absence of clinically relevant depression; scores between 6 and 13 indicate mild depression; from 14 to 18 moderate depression; from 19 to above severe depression [35].”
BackgroundMethodIntegrative Therapies for Depression : Redefining Models for Assessment, Treatment and Prevention
Greenblatt, J. M., & Brogan, K. (2015) · CRC Press eBooks · Cited by 8
Quaranta, S., Dupouey, J., Colle, R., & Verstuyft, C. (2017) · Therapies · doi:10.1016/j.therap.2016.09.012 · Cited by 9
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Moeller, S., Lücke, C., Heinen, C., Bewernick, B. H., Aydın, M., Lam, A. P., Grömer, T. W., Philipsen, A., & Müller, H. (2019) · Journal of Visualized Experiments · doi:10.3791/58264 · Cited by 13
Flint, A. J., Bingham, K. S., Neufeld, N. H., Alexopoulos, G. S., Mulsant, B. H., Rothschild, A. J., Whyte, E. M., Voineskos, A. N., Marino, P., & Meyers, B. S. (2021) · Psychological Medicine · doi:10.1017/s0033291721000805 · Cited by 11
“…phase baseline variables: current age, 17- item HAM-D total score, SADS delusion severity score, HADS-A total score, CIRS-G total score, episode duration, and treatment resistance during the index episode of depression (Kemp, Gordon, Rush, & Williams, 2008; Perlman et al., 2019; Rush et al., 2006).”
BackgroundPerugi, G., Calò, P., Filippis, S. D., Rosso, G., Vita, A., Adami, M., Ascione, G., Morrens, J., & Delmonte, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.769693 · Cited by 9
“While the therapeutic goal of MDD is remission with complete functional recovery (5), a sizeable subgroup of patients reports residual or persistent symptoms of depression despite receiving evidence-based antidepressant treatments (6).”
BackgroundKluczniok, D., Dittrich, K., Attar, C. H., Bödeker, K., Roth, M., Jaite, C., Winter, S., Herpertz, S. C., Roepke, S., Heim, C. C., et al. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0688-4 · Cited by 10
Mitchell, A. J., & de Santiago, A. I. (2009) · Actas Españolas de Psiquiatría · Cited by 14
Developing the evidence for evidence-based practice
Rush, A. J. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080202 · Cited by 9
“Remission is the preferred, most valid and most clinically relevant outcome, because it is associated with a return to normal function(3) and a better prognosis compared with response.(4,5) Although these first-step, short-term efficacy trials may be essential, they provide little information to clinicians or patients…”
BackgroundSelf-citationCitrome, L., Reda, I., & Kerolous, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.040 · Cited by 9
Colle, R., Chappell, K., Asmar, K. E., Fève, B., Chanson, P., David, D. J. P., Verstuyft, C., Becquemont, L., & Corruble, E. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.05.025 · Cited by 10
Sun, Y., Liu, X., Li, Y., Zhi, Q., & Xia, Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1485878 · Cited by 10
Improving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18207 · Cited by 9
Self-citationModeling the Risks and Benefits of Depression Treatment for Children and Young Adults
Soeteman, D. I., Miller, M., & Kim, J. J. (2012) · Value in Health · doi:10.1016/j.jval.2012.03.1390 · Cited by 12
“, an improvement score of 1 [very much improved] or 2 [much improved] on the Clinical Global Impressions-Improvement and a Children’s Depression Rating ScaleRevised score of 29 or more) [6]; during partial symptom relief, the competing events that are possible include relapse into a depressive episode, suicide attempt…”
BackgroundStamouli, S. S., Yfantis, A., Lambousis, E., Liakouras, A., Lagari, V., Tzanakaki, M., Giailoglou, D., Legault, M., & Parashos, I. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902810375 · Cited by 7
“The objective of this study was to evaluate the effectiveness of escitalopram (flexible dose, 10 – 20 mg/day) for the treatment of MDD in a large heterogeneous sample of patients, with or without comorbid conditions, in a naturalistic outpatient setting in Greece.”
BackgroundInfluentialShah, D., Vaidya, V., Patel, A. S., Borovicka, M. C., & Goodman, M.-H. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1417-0 · Cited by 10
Henigsberg, N., Savić, A., Radoš, M., Radoš, M., Šarac, H., Šečić, A., Janović, M. B., Foro, T., Ozretić, D., Turk, V. E., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05303-2 · Cited by 8
Rigal, A., Colle, R., Asmar, K. E., Trabado, S., Loeb, E., Martin, S., Choucha, W., Gressier, F., Costemale-Lacoste, J.-F., de Larminat, D., et al. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419893433 · Cited by 12
“Response was defined by a decrease in the HDRS total score of at least 50% from baseline to follow-up (Rush et al., 2006).”
MethodKeith, J. A., Verdeli, H., & Vousoura, E. (2011) · International Journal of Mental Health · doi:10.2753/imh0020-7411400301 · Cited by 8
“Depression treatment researchers, however, have defined normative in terms specific to depression symptoms, rather than relying on more broad-based definitions [21, 22].”
BackgroundMethodInfluentialCurrent drug targets for the treatment of depression
Pathak, G., Nigade, A., Anitha, K., & Bhatt, S. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100270 · Cited by 9
Why Recurrent Depression Should Be Reconceptualized and Redefined
Monroe, S. M., & Harkness, K. L. (2023) · Current Directions in Psychological Science · doi:10.1177/09637214221143045 · Cited by 6
Fuhr, D. C., Sikander, S., Vanobberghen, F. M., Weobong, B., Rahman, A., & Weiss, H. A. (2023) · Cambridge Prisms Global Mental Health · doi:10.1017/gmh.2023.26 · Cited by 8
Walker, N. C., Philip, N. S., Kozel, F. A., Yesavage, J. A., & Madore, M. R. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.10.010 · Cited by 8
Schulberg, H. C., Belnap, B. H., Houck, P. R., Mazumdar, S., Reynolds, C. F., & Rollman, B. L. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31820d9416 · Cited by 6
Kluczniok, D., Bertsch, K., Attar, C. H., Neukel, C., Fuchs, A. K., Jaite, C., Dittrich, K., Bödeker, K., Heinz, A., Winter, S., et al. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104791 · Cited by 7
Fava, V. A. R., Sarin, L. M., Lucchese, A. C., Sant, L. C. D., Magalhães, E. T. P., Delfino, R. S., Tuena, M. A., Nakahira, C., Jackowski, A. P., Abdo, G. L., et al. (2020) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsm.2020.10.003 · Cited by 6
Litwińska-Bołtuć, M., Święcicki, Ł., Sprečo, A., & Timpka, T. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03088-3 · Cited by 5
“The additional time needed for recovery varies in the literature, ranging from 8 weeks of continuous remission to 4 months [32, 35].”
BackgroundRush, A., Madia, N. D., Carmody, T., & Trivedi, M. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s342457 · Cited by 6
Self-citationHu, Y., Nassan, M. M., Singh, B., Croarkin, P. E., & Kung, S. (2022) · Psychiatry Research Communications · doi:10.1016/j.psycom.2022.100033 · Cited by 6
Asmar, K. E., Annan, N. B., Khoury, R., Colle, R., Martin, S., Ghoul, T. E., Trabado, S., Chanson, P., Fève, B., Verstuyft, C., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291722003919 · Cited by 9
“RTT was measured at M3 and M6 using the Hamilton Rating Scale for Depression (HDRS) scale: a 50% decrease from baseline HDRS score indicated that the patient responded to treatment (Rush et al., 2006).”
MethodOliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N. J., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250987 · Cited by 9
AlRuthia, Y. S., Hong, S. H., & Solomon, D. K. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.06.001 · Cited by 6
Edinger, J. D., Manber, R., Buysse, D. J., Krystal, A. D., Thase, M. E., Gehrman, P. R., Fairholme, C. P., Luther, J. F., & Wisniewski, S. R. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6448 · Cited by 7
“Remission was defined following American College of Neuro - psychopharmacology recommendations (ACNP) 31 by presence of the following 2 conditions for at least 3 consecutive weeks: (a) absence of both depressed mood and anhedonia; and (b) no more than 2 other DSM-IV-TR diagnostic criterion symptoms of depression.”
InfluentialSelf-citationVittengl, J. R., Stutzman, S. E., Atluru, A., & Jarrett, R. B. (2019) · Behavior Therapy · doi:10.1016/j.beth.2019.10.008 · Cited by 6
“Finally, the RCT was not designed to test mechanisms (e.g., behavioral, cognitive, genetic, and their interactions) connecting SLE and CT skills with response and relapse/recurrence, and limited sample size may have led to missed effects, especially in the smaller post-acute sample.”
BackgroundInfluentialElectroconvulsive therapy for depression
Munkholm, K., Jørgensen, K. J., & Paludan‐Müller, A. S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013843 · Cited by 7
Alexander, J. L., Richardson, G., Grypma, L., & Hunkeler, E. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11s.s59 · Cited by 6
“Limitations of the STAR*D trial were described by Rush et al. (2006) as lack of placebo control and unblinded delivery of antidepressants. For an excellent discussion with recommendations on response and remission in the treatment of major depression, the reader is referred to the report by the American College of Neu…”
BackgroundMethodTreatment Resistant Depression
Hembram, M., & Chaudhury, S. (2021) · Eastern Journal of Psychiatry · doi:10.5005/ejp-13-1--2-77 · Cited by 7
“and course of TRD (behavioral phenotype), (2) neurobiological profile (EEG, neuroimaging, genetics, laboratory studies), and (3) the context and environment in which TRD develops.”
BackgroundMethodDwivedi, Y., & Roy, B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03396-0 · Cited by 7
“Despite the availability of a broad array of antidepressants, remission rates among MDD patients remain very low [5, 6].”
Weekly transcranial magnetic stimulation (TMS) maintenance: a case series
Rybak, M., Peterson, G. M., PRIDMORE, S. A., Turnier‐Shea, Y., Byrne, K., & Dillon, T. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2416385 · Cited by 5
Conway, C. R., Rush, A. J., Gordon, C., Preskorn, S., Sackeïm, H. A., Aaronson, S. T., McIntyre, R. S., Lee, Y.-C. (., Shy, O., Tran, Q., et al. (2025) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2025.100121 · Cited by 6
“In addition, symptom response has historically been declared when at least a 50 % reduction in baseline symptom severity occurs [6 – 10].”
Self-citationVittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2015) · Psychological Medicine · doi:10.1017/s0033291715001191 · Cited by 5
Self-citationAlejandre-Lara, A. L., Canby, N. K., Wesbecher, K. D., Eichel, K., Britton, W. B., & Lindahl, J. R. (2022) · Cognitive Therapy and Research · doi:10.1007/s10608-021-10287-5 · Cited by 6
“Positive treatment response was defined as a ≥ 50% reduction in depression symptoms from baseline to 20 weeks (Rush et al., 2006).”
MethodResidual symptoms following electroconvulsive therapy: A retrospective cohort study
Hart, K. L., McCoy, T. H., Henry, M., Seiner, S. J., & Luccarelli, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.135 · Cited by 5
Sheehan, J. J., LaVallee, C., Maughn, K., Balakrishnan, S., Pesa, J. A., Joshi, K., & Nelson, C. J. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0091 · Cited by 5
“Similarly, some treatment guidelines [18–20] and a recent naturalistic study [25] recommend applying shorter time frames (2–6 weeks) to detect non-response and trigger treatment modification than was used in this analysis, which would also classify more patients as experiencing treatment inertia…”
BackgroundSchoepf, D., & Neudeck, P. (2011) · InTech eBooks · doi:10.5772/26058 · Cited by 8
Metadata
- Authors
- Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., Regier, D. A., Rosenbaum, J. F., Ray, O., & Schatzberg, A. F.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Stanford Medicine (US)
- University of Pittsburgh (US)
- Emory University (US)
- University of Arizona (US)
- American Psychiatric Association (US)
- Harvard University (US)
- Vanderbilt University (US)
- Corresponding author
- Rush, A John
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-06-21
- Volume
- 31
- Issue
- 9
- Pages
- 1841-1853
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2039979496
- Cited by
- 707
- References
- 132
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 29 · 2023: 58 · 2022: 30 · 2021: 47 · 2020: 30 · 2019: 47 · 2018: 35 · 2017: 30 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 36 · 2012: 35
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, remission, response, recovery, relapse, recurrence, end points, symptom rating scales, DSM-IV-TR diagnostic criteria, clinical trial results, quality of life
- MeSH terms
- Clinical Trials as Topic, Major Depressive Disorder, Humans, Recurrence, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.